Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
Tóm tắt
Từ khóa
Tài liệu tham khảo
Stamler, 1993, Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial, Diabetes Care, 16, 434, 10.2337/diacare.16.2.434
Chen, 1991, Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations, BMJ, 303, 276, 10.1136/bmj.303.6797.276
Rossouw, 1990, The value of lowering cholesterol after myocardial infarction, N Engl J Med, 323, 1112, 10.1056/NEJM199010183231606
Oliver, 1991, Might treatment of hypercholesterolaemia increase non-cardiac mortality?, Lancet, 337, 1529, 10.1016/0140-6736(91)93208-Q
Davey Smith, 1992, Should there be a moratorium on the use of cholesterol lowering drugs?, BMJ, 304, 431, 10.1136/bmj.304.6824.431
Law, 1994, Assessing possible hazards of reducing serum cholesterol, BMJ, 308, 373, 10.1136/bmj.308.6925.373
Jacobs, 1992, Report of the Conference on low blood cholesterol: mortality associations, Circulation, 86, 1046, 10.1161/01.CIR.86.3.1046
Law, 1994, By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?, BMJ, 308, 367, 10.1136/bmj.308.6925.367
Muldoon, 1990, Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials, BMJ, 301, 309, 10.1136/bmj.301.6747.309
Tobert, 2003, Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors, Nat Rev Drug Discov, 2, 517, 10.1038/nrd1112
1995, Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens, Am J Cardiol, 75, 1130, 10.1016/S0002-9149(99)80744-9
1990
1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383
Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001
Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401
1997, The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts, N Engl J Med, 336, 153, 10.1056/NEJM199701163360301
Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615
1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902
2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?, Ital Heart J, 1, 810
Serruys, 2002, Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial, JAMA, 287, 3215, 10.1001/jama.287.24.3215
2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3
Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X
2002, Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care, JAMA, 288, 2998, 10.1001/jama.288.23.2998
Holdaas, 2003, Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, ranomised, placebo-controlled trial, Lancet, 361, 2024, 10.1016/S0140-6736(03)13638-0
Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5
Athyros, 2002, Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention, Curr Med Res Opin, 18, 220, 10.1185/030079902125000787
Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499
Cannon, 2004, Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583
Nissen, 2004, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial, JAMA, 291, 1071, 10.1001/jama.291.9.1071
LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461
Pedersen, 1999, Effect of greater LDL-C reductions on prognosis: the Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) trial, Atherosclerosis, 144, 38, 10.1016/S0021-9150(99)80143-9
Cullen, 1997, Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering, Am J Cardiol, 80, 1287, 10.1016/S0002-9149(97)00667-X
Schwartz, 2001, Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study—a randomized controlled trial, JAMA, 285, 1711, 10.1001/jama.285.13.1711
2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7
Cummings, 1994, The association between cholesterol and death from injury, Ann Intern Med, 120, 848, 10.7326/0003-4819-120-10-199405150-00006
Law, 1991, Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies, Cancer Causes Control, 2, 253, 10.1007/BF00052142
1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. I: reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025
Frick, 1987, Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001
Poynter, 2005, Statins and the risk of colorectal cancer, N Engl J Med, 352, 2184, 10.1056/NEJMoa043792
Shannon, 2005, Statins and prostate cancer risk: a case-control study, Am J Epidemiol, 162, 318, 10.1093/aje/kwi203
Grundy, 2004, Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E
De Backer, 2004, European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice, Atherosclerosis, 171, 145